MEP Meeting on Brain Health and Neurological Conditions

“Knowledge and awareness are crucial in recognizing neurological conditions” as they often are invisible, even to doctors – this was one of the major issues that patients and patient advocates brought up at the MEP meeting with the Interest Group Brain Health and Neurological Conditions, organized by EFNA. This would lead to many patients feeling blamed for their disease, when hearing things like “it’s something psychological” or “you’re doing this by yourself”. So, educating and thus empowering patients in being able to better estimate their own condition is also important. They also emphasized the need of going “beyond medicine, as there is also the social dimension,” meaning the patient is not the only patient, but also their families.

MEPs Tomislav Sokol and Tilly Metz highlighted the importance of the new EHDS (European Health Data Space), as it will connect specialized centers and allow a cross-border data sharing, which will be a crucial step towards faster and more precise diagnoses, but also in terms of research and creating new medicines and treatment. And lastly to also allow patients to be involved about how their data is used and shared. Looking into accessibility to medicine within the EU, there is a huge discrepancy between the different countries – and “this sends a completely wrong message – the access to life-saving medicine should not depend on geography”, said MEP Romana Jerković. So facilitating access in all member states is the next big step.

Our coordinator Holm Graessner addressed the need of sustaining the ERNs – on European as well as on national levels – and encouraged to also make more use of the ERNs, for research as well as for HTA (Health Technology Assessment) purposes. Both policy asks were being fully supported by the MEPs: “We need to sustain the funding for ERNs [… and] use ERNs much stronger than we are doing now”, said Tomislav Sokol.

Solve-RD: Interview with coordinator Holm Graessner

Within the Solve-RD project, over 300 experts from different European countries and Canada re-analysed genome data from undiagnosed 6447 patients. They were able to diagnose 506 patients and their families. For 15% of the patients, there are leads for actionability, in some including treatment; in other cases, the diagnosis provides clarity for the patients and their families.

Find the press release here.

Learn more in the paper: Laurie, S., Steyaert, W., de Boer, E. et al. Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses. Nat Med (2025). https://www.nature.com/articles/s41591-024-03420-w

Holm Graessner becomes Lancet Commissioner

Our coordinator Holm Graessner is now commissioner for the freshly launched Rare Diseases International Lancet Commission on Rare Diseases (RDI-LCRD)! We feel really honoured that among the 27 commissioners from all over the world he is the only one coming from an ERN.

The initiative is dedicated to generating evidence- and equity-informed recommendations that are implementable and impactful across all countries to dramatically improve the lives of PLWRD. The RDI-LCRD brings together 27 Commissioners who represent countries from around the world and bring diverse perspectives (gender, lived experience) and expertise (ethics, clinical care, research, biostatistics, economics, regulatory, technology, innovation) from a variety of healthcare systems.  

Find more information here: press release, website, project description  (registration for FREE account required), LinkedIn.

Meeting with MEPs for Rare Disease Day

Rare Disease Day is coming up! Join us for shaping the future on policy for Rare Neurological Diseases on February 19, 10-12 CET. Join the meeting with the MEP Interest Group Brain Helath & Neurological Conditions together with our coordinator Holm Graessner as panelist.

Big thanks to the European Federation of Neurological Associations (EFNA) for this invitation! To participate on-site or online please register till February 5: https://www.efna.net/mep-february25/

ERN-RND now on BlueSky!

You can now find us on BlueSky: @ern-rnd.bsky.social

Did you know that BlueSky was conceptualized in 2019 by former Twitter CEO Jack Dorsey and developed in parallel with Twitter? This is why it looks and functions pretty similar like twitter. So, moving from X to BlueSky is very easy, as everything is familiar – and it’s even in the same blue as twitter was!

Try it out and follow us to BlueSky. We hope to see you there soon!

NGS: European Quality Assessment for ERN-RND centers

Why is a quality assessment on European level important for next generation seuencing (NGS)? What needs to be improved and what’s the benefit of having a network of expert centers like ERN-RND to work with?

Ales Maver, clinical laboratory scientist at the University Medical Center in Ljubljana, talks about the insights and outcomes of the quality assessment for NGS that was done within the ERN-RND network 2024 in this video:

For more Information, see paper:
Quality assurance for next-generation sequencing diagnostics of rare neurological diseases in the European Reference Network.

Aleš Maver, Katja Lohmann, Fran Borovečki, Nicola Wolstenholme, Rachel L. Taylor, Malte Spielmann, Tobias B. Haack, Matthias Gerberding, Borut Peterlin & Holm Graessner

6th ERN-RND Winter School

The European Pediatric Neurology Society (EPNS) and the European Reference Network for Rare Neurological Diseases (ERN-RND) are organizing a Winter School on Challenges of Treating Rare Neurological Diseases.

The school will take place virtually, from 12th to 14th March 2025.

Day 1 Disease Modifying Therapies
Day 2 Movement Disorders
Day 3 Co-morbidities and Cases

Find the programme here.

Registration